{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:54:37Z","timestamp":1781978077456,"version":"3.54.5"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Diabetic foot ulcer (DFU), a severe chronic complication of diabetes mellitus, poses a major public health threat due to its high rates of disability, recurrence, and all-cause mortality. The mortality rate of DFU patients is closely related to cardiovascular events, indicating that their treatment should go beyond local wound management and focus on cardiovascular risk intervention. Glucagon-like peptide-1 receptor agonists (GLP-1 RA), known for their cardiovascular protective effects demonstrated in cardiovascular outcome trials, offer new treatment opportunities for DFU patients. However, the pharmacological properties of GLP-1 RA that suppress appetite and delay gastric emptying may exacerbate malnutrition in DFU patients during the acute infection phase, limiting their use. This review aims to systematically describe personalized application strategies for GLP-1 RA based on the clinical staging differences in DFU patients. Additionally, it compares the clinical translational potential of mono-, dual-, and triple-target GLP-1 RA drugs and evaluates their adverse effects on DFU patients, with the aim of providing more rational and structured treatment strategies for improving the long-term prognosis of DFU patients.<\/jats:p>","DOI":"10.3389\/fendo.2025.1754925","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:36:23Z","timestamp":1768973783000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Potential application of mono-, dual-, and triple-target GLP-1 receptor agonists in improving the prognosis of patients with diabetic foot ulcers"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhe","family":"Li","sequence":"first","affiliation":[{"name":"Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Basic Medical Sciences, Henan University of Science and Technology","place":["Luoyang, China"]},{"name":"People\u2019s Hospital of Baofeng","place":["Pingdingshan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"He","sequence":"additional","affiliation":[{"name":"Yibin Vocational College of Medicine and Health","place":["Yibin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyan","family":"Hu","sequence":"additional","affiliation":[{"name":"Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Liu","sequence":"additional","affiliation":[{"name":"Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Senior Department of Nephrology, The First Medical Center of Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, National Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Ma","sequence":"additional","affiliation":[{"name":"Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1615439","article-title":"Diabetic foot ulcers and their recurrence","volume":"376","author":"Armstrong","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e3657","DOI":"10.1002\/dmrr.3657","article-title":"Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update)","volume":"40","author":"Schaper","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/dom.14840","article-title":"Global mortality of diabetic foot ulcer: A systematic review and meta-analysis of observational studies","volume":"25","author":"Chen","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/jama.2023.10578","article-title":"Diabetic foot ulcers: A review","volume":"330","author":"Armstrong","year":"2023","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-03696-5","article-title":"Diabetic foot ulcer is associated with cardiovascular-related mortality and morbidity \u2013 a systematic review and meta-analysis of 8062 patients","volume":"84","author":"Chin","year":"2024","journal-title":"Endocrine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16498","article-title":"The use of SGLT2 inhibitors in people with diabetes-related foot disease: A Delphi-based consensus study","volume":"27","author":"Highton","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-0292","article-title":"Differential effect of GLP-1 receptor agonists and SGLT2 inhibitors on lower-extremity amputation outcomes in type 2 diabetes: A nationwide retrospective cohort study","volume":"48","author":"Hong","year":"2025","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e026586","DOI":"10.1161\/JAHA.122.026586","article-title":"Liraglutide accelerates ischemia-induced angiogenesis in a murine diabetic model","volume":"12","author":"Zhu","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.14336","article-title":"Liraglutide ameliorated peripheral neuropathy in diabetic rats: Involvement of oxidative stress, inflammation and extracellular matrix remodeling","volume":"146","author":"Moustafa","year":"2018","journal-title":"J Neurochem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.660263","article-title":"Liraglutide via activation of AMP-activated protein kinase-hypoxia inducible factor-1\u03b1-heme oxygenase-1 signaling promotes wound healing by preventing endothelial dysfunction in diabetic mice","volume":"12","author":"Huang","year":"2021","journal-title":"Front Physiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/nu13082576","article-title":"Associations between nutrients and foot ulceration in diabetes: A systematic review","volume":"13","author":"Bechara","year":"2021","journal-title":"Nutrients"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/cdn\/nzaa040_008","article-title":"Nutritional intervention improves the dietary intake of essential micronutrients in patients with diabetic foot ulcers","volume":"4","author":"Basiri","year":"2020","journal-title":"Curr Dev Nutr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11894-025-00995-3","article-title":"Gastrointestinal motility effects of GLP-1 receptor agonists","volume":"27","author":"Bellavance","year":"2025","journal-title":"Curr Gastroenterol Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with glp-1 receptor agonists: A multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/14791641251322909","article-title":"The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study","volume":"22","author":"Lewis","year":"2025","journal-title":"Diabetes Vasc Dis Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.ijem_423_21","article-title":"Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis","volume":"25","author":"Dutta","year":"2021","journal-title":"Indian J Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2023.171003","article-title":"The molecular pharmacology of glucagon agonists in diabetes and obesity","volume":"165","author":"Novikoff","year":"2023","journal-title":"Peptides"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2337\/db24-1856-LB","article-title":"1856-LB: efficacy and safety of mazdutide in chinese participants with overweight or obesity (GLORY-1)","volume":"73","author":"Ji","year":"2024","journal-title":"Diabetes"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101483","article-title":"Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial","volume":"7","author":"Browne","year":"2025","journal-title":"JHEP Rep"},{"key":"B27","unstructured":"ClinicalTrials.gov\n          Study details | NCT06077864 | A study to test the effect of survodutide (BI 456906) on cardiovascular safety in people with overweight or obesity (SYNCHRONIZE\u2122 - CVOT)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013hormone-receptor agonist retatrutide for obesity \u2014 A phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00092-0","article-title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","volume":"13","author":"Coskun","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12933-015-0229-9","article-title":"Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes","volume":"14","author":"Xiao","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12933-015-0190-7","article-title":"Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients","volume":"14","author":"Zhang","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"B35","unstructured":"Liskiewicz\n              D\n            \n          \n          An unimolecular GLP-1R\/GIPR\/Pan-PPAR quintuple agonist eliminates obesity and insulin resistance in mice"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-03183-3","article-title":"Anti-obesity drugs\u2019 side effects: what we know so far","volume":"622","author":"Lenharo","year":"2023","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae120","article-title":"Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node","volume":"120","author":"Lubberding","year":"2024","journal-title":"Cardiovasc Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1754925\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:36:26Z","timestamp":1768973786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1754925\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":38,"alternative-id":["10.3389\/fendo.2025.1754925"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1754925","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"article-number":"1754925"}}